The feasibility study of docetaxel in patients with anaplastic thyroid cancer

Japanese Journal of Clinical Oncology

Volumn 40, Issue 6, 2010, Pages 596-599

  Kawada, Kenji ^a,b   Kitagawa, Koichi ^a   Kamei, Sachi ^a   Inada, Megumi ^a   Mitsuma, Ayako ^a   Sawaki, Masataka ^a   Kikumori, Toyone ^a   Fujimoto, Yasushi ^a   Arima, Hiroshi ^a   Imai, Tsuneo ^a   Ando, Yuichi ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

Author keywords

Anaplastic thyroid cancer; Chemotherapy; Docetaxel

Indexed keywords

DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN ANTAGONIST; ANTINEOPLASTIC AGENT; TAXOID;

AGED; ANAPLASTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DRUG EFFICACY; EXTERNAL BEAM RADIOTHERAPY; FEASIBILITY STUDY; FEMALE; HUMAN; LUNG METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROSPECTIVE STUDY; THYROID CANCER; TREATMENT DURATION; TREATMENT RESPONSE; CARCINOMA; DISEASE COURSE; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; METASTASIS; PATHOLOGY; THYROID TUMOR;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; TAXOIDS; THYROID NEOPLASMS;

EID: 77953393558     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyq025     Document Type: Article

References (13)

1. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2683-48.
2. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999;84:4043-9.
3. Sugino K, Ito K, Mimura T, Nagahama M, Fukunari N, Kubo A, et al. The important role of operations in the management of anaplastic thyroid carcinoma. Surgery 2002;131:245-8.
4. Kim JH, Leeper RD. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987;60:2372-5.
5. Levendag PC, De Porre PM, van Putten WL. Anaplastic carcinoma of the thyroid gland treated by radiation therapy. Int J Radiat Oncol Biol Phys 1993;26:125-8.
6. Shimokata K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155-60.
7. Ahuja S, Ernst H. Chemotherapy of thyroid carcinoma. J Endocrinol Invest 1987;10:303-10.
8. De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, et al. Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 1991;14:475-80.
9. Asakawa H, Kobayashi T, Komoike Y, Maruyama H, Nakano Y, Tamaki Y, et al. Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. Anticancer Res 1997;17:2757-62.
10. Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Res 1986;70:405-7.
11. Kurukahvecioglu O, Ege B, Poyraz A, Tezel E, Taneri F. Anaplastic thyroid carcinoma with long term survival after combined treatment: case report. Endocr Regul 2007;41:41-4.
12. Ain KB, Egorin MJ, Desimone PA. Treatment of anaplastic thyroid carcinoma with paclitaxel: phase II trial using ninety-six hour infusion. Collaborative anaplastic thyroid cancer health intervention trials (CATCHIT) group. Thyroid 2000;10:587-94.
13. Rischin D, Ackland SP, Smith J, Garg MB, Clarke S, Millward MJ, et al. Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor; but not with prophylactic antibiotics. Ann Oncol 2002;13:1810-8.